- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Alamar Biosciences Prices Upsized IPO at $17 Per Share
The precision proteomics company raised $191.3 million in its Nasdaq debut.
Apr. 17, 2026 at 1:33am
Got story updates? Submit your updates here. ›
Alamar Biosciences' precision proteomics platform aims to unlock new frontiers in early disease detection through advanced biomarker analysis.Fremont TodayAlamar Biosciences, a California-based life sciences company focused on early disease detection through precision proteomics, announced the pricing of its upsized initial public offering. The company sold 11.25 million shares of common stock at $17 per share, raising approximately $191.3 million before underwriting fees and other expenses. Alamar's shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol 'ALMR' on April 17, 2026.
Why it matters
Alamar's IPO represents a significant milestone for the company as it seeks to commercialize its proprietary NULISA technology and ARGO HT System, which are designed to detect disease biomarkers with ultra-high sensitivity. The additional capital will help Alamar advance its precision proteomics platform and expand its efforts to enable earlier disease detection.
The details
The IPO was upsized from the original plan, with Alamar selling 11.25 million shares instead of the initial 10 million. The company also granted the underwriters a 30-day option to purchase up to an additional 1.69 million shares. J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners and Stifel acted as joint book-running managers for the offering.
- Alamar's shares are expected to begin trading on the Nasdaq on April 17, 2026.
- The IPO is expected to close on April 20, 2026.
The players
Alamar Biosciences, Inc.
A life sciences company dedicated to advancing the early detection of disease through its proprietary precision proteomics technology.
J.P. Morgan
One of the joint book-running managers for Alamar's IPO.
BofA Securities
One of the joint book-running managers for Alamar's IPO.
TD Cowen
One of the joint book-running managers for Alamar's IPO.
Leerink Partners
One of the joint book-running managers for Alamar's IPO.
Stifel
One of the joint book-running managers for Alamar's IPO.
What’s next
Alamar's shares are expected to begin trading on the Nasdaq Global Select Market on April 17, 2026 under the ticker symbol 'ALMR'.
The takeaway
Alamar's successful IPO demonstrates investor confidence in the company's precision proteomics technology and its potential to enable earlier disease detection. The additional capital will help Alamar advance its platform and expand its efforts to commercialize its innovative solutions.
